Slight weight loss; but also a slight rise in blood pressure..

Prescrire International

Volumn 10, Issue 55, 2001, Pages 140-145

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450; DEXFENFLURAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLITE; ERYTHROMYCIN; FENFLURAMINE; KETOCONAZOLE; LITHIUM; NIFEDIPINE; NORADRENALIN; OPIATE; ORAL ANTIDIABETIC AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SIBUTRAL; SIBUTRAMINE; SUMATRIPTAN; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL; CYCLOBUTANE DERIVATIVE;

ARTICLE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG STRUCTURE; FRANCE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; KINESIOTHERAPY; LIPID BLOOD LEVEL; MORBID OBESITY; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SKIN TINGLING; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA; APPETITE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; OBESITY; TREATMENT OUTCOME;

APPETITE; APPETITE DEPRESSANTS; CLINICAL TRIALS; CYCLOBUTANES; FRANCE; HUMANS; HYPERTENSION; OBESITY; TREATMENT OUTCOME;

EID: 0037782686     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Prescrire Editorial Staff "Valve disease and pulmonary arterial hypertension" Prescr Int 2000; 9 (45): 211.
2. Prescrire Editorial Staff "Orlistat" Prescr Int 1999; 8 (42): 99-104.
3. Heal DJ et al. "Sibutramine: a novel anti-obesity drug - A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine" Int J Obes 1998; 22 (suppl. 1): 18-29.
4. Kelly F et al. "Sibutramine: weight loss in depressed patients" Int J Obes 1995; 19 (suppl. 2) (abstr. P397): 145.
5. Rolls BJ et al. "Sibutramine reduces food intake in non-dieting women with obesity" Obes Res 1998; 6 (1): 1-11.
6. McNeely W and Goa KL "Sibutramine - A review of its contribution to the management of obesity" Drugs 1998; 56 (6): 1093-1124.
7. Bray GA et al. "Sibutramine produces dose-related weight loss" Obes Res 1999; 7 (2): 189-198.
8. Bray GA et al. "Sibutramine - dose response and long-term efficacy in weight loss, a double-blind study" Int J Obes 1994; 18 (suppl. 2) (abstr. 0231): 60.
9. Jones SP et al. "Long term weight loss with sibutramine" Int J Obes 1995; 19 (suppl. 2) (abstr. 071): 41.
10. Smith IG et al. "Categorical outcome analysis of weight loss in long term sibutramine treatment" Int J Obes 1996; 20 (suppl. 4) (abstr. 20-520-FP3): 157.
11. Food and Drug Administration "Medical officer's review of the original submission of NDA 20-632" 10 May 1996: 165 pages.
12. Apfelbaum M et al. "Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine" Am J Med 1999; 106: 179-184.
13. Fanghänel G et al. "A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity" Int J Obes 2000; 24: 144-150.
14. Cuellar GEM et al. "Six-month treatment of obesity with sibutramine 15 mg; a double-blind placebo-controlled monocenter clinical trial in a hispanic population" Obes Res 2000; 8 (1): 71-82.
15. Hauner H et al. "Weight reduction by sibutramine in obese subjects in primary care medicine: the S.A.T. study" Int J Obes 2000; 24 (suppl. 1) (abstr. 32): S100.
16. James WPT et al. "Effect of sibutramine on weight maintenance after weight loss: a randomised trial" Lancet 2000; 356: 2119-2125.
17. Rissanan A "Sibutramine in the treatment of obese type II diabetics" Int J Obes Relat Metab Disord 1999; 23 (suppl.) (abstr. 167): S63.
18. Heath MJ et al. "Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus" Diabetes 1999; 48 (suppl. 1) (abstr, 1346 : A308.
19. McNulty S et al. "Sibutramine is effective for weight loss in obese, metformin-treated type 2 diabetics" Int J Obes 2000; 24 (suppl. 1) (abstr. 320): S100.
20. Fujioka K et al. "Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus" Diab Obes Metab 2000; 2: 175-187.
21. Weinstein SP et al. "Sibutramine enhances weight loss in obese hypertensive patients taking angiotensin converting enzyme (ACE) inhibitors" Int J Obes Relat Metab Disord 1998; 22 (suppl. 3) (abstr. 0241): S65.
22. McMahon FG et al. "Efficacy and safety of sibutramine in obese white and african american patients with hypertension" Arch Intern Med 2000; 160: 2185-2191.
23. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products "Note for guidance on clinical investigation of drugs used in weight control" 17 December 1997: 7 pages.
24. Food and Drug Administration "Statistical review and evaluation NDA 20-632" 4 April 1996: 37 pages.
25. "Meridia°". In: 'Physicians' Desk Reference" Medical Economics Company, Montvale 2001: 1637-1641.
26. Food and Drug Administration "Medical review NDA 20-632" 27 June 1996: 15 pages.
27. Lean MEJ et al. "Sibutramine in the treatment of obese patients with dyslipidaemia". Summary of a conference communication available from the website www.reductil.ch consulted on 3 July 2000.
28. Prescrire Editorial Staff "Anorectics and severe heart valve disease" Prescr Int 199; 7 (33): 19-20.
29. Food and Drug Administration "HFD - 510 consult. Abuse liability assessment" 7 October 1997: 48 pages.
30. Schuh LM et al. "Abuse liability assessment of sibutramine, a novel weight control agent" Psychopharmacology 2000; 147 (4): 339-346.
31. Prescrire Editorial Staff "Drug interactions with selective serotonin reuptake inhibitors" Prescr Int 2001; 10 (51): 25-31.
32. Seagle HM et al. "Effects of sibutramine on resting metabolic rate and weight loss in overweight women" Obes Res 1998; 6 (2): 115-121.
33. Bach DS et al. "Absence of cardiac valve dysfunction in obese patients treated with sibutramine" Obes Res 1999; 7 (4): 363-369.
34. Food and Drug Administration "Statistical review and evaluation NDA 20-632" 14 November 1997: 6 pages.
35. Zannad F et al. "Sibutramine's effects on ventricular dimensions and heart valves in obese patients during weight reduction" 10th ECO, Anvers 24-27 May 2000: 1 page.